Back to research

Research paper

DEE-SWAS: A retrospective cohort study from a tertiary center

Tertiary pediatric neurology center cohort of DEE-SWAS patients. Reports etiology distribution, SWI quantification, treatment response patterns, and outcomes. Cited twice in the 2026 Manus AI review (refs [4] and [6]).

Indexed context

Hanci F, et al.

dee-swascohorttertiary-center2026

Markdown path

content/research/papers/2026-hanci-dee-swas-tertiary-cohort.md

Findings

Tertiary pediatric neurology center cohort of DEE-SWAS patients. Reports etiology distribution, SWI quantification, treatment response patterns, and outcomes. Cited twice in the 2026 Manus AI review (refs [4] and [6]).

Why it may matter for Levi

Contemporary 2026 cohort data provides benchmark for Levi's case. Useful for comparing his etiology-unknown status, treatment response (near-total electrographic resolution on IV pulse), and likely prognostic trajectory against a recent real-world cohort.

Paper text

Hanci et al. (2026) — DEE-SWAS retrospective tertiary-center cohort

Source

  • Epileptic Disorders, 2026. Turkish tertiary pediatric-neurology center.

Why in corpus

Contemporary clinical-characteristics and treatment-response cohort describing the current DEE-SWAS population.

Key findings

  • DEE-SWAS accounts for approximately 0.5–0.6% of childhood epilepsies.
  • Peak onset between ages 4 and 8; male predominance.
  • Clinical characteristics, treatment responses, and outcomes reported consistent with prior pooled analyses.

Levi-relevant takeaways

  • Epidemiological anchor — Levi (onset ~2.5 years) is at the early end of the age-of-onset distribution, which per the Van Arnhem 2025 IQ-trajectory paper is associated with the continued-decline rather than partial-recovery stratum.
  • Confirms rarity of the condition — provides context for why family-to-family references are hard to find and why clinical-trial populations are small.
  • No new treatment implications beyond what the Lapid & Varughese 2026 review captures.